Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review)
- Authors:
- Shan-Qiang Zhang
- Su-Ming Pan
- Si-Xian Liang
- Yu-Shuai Han
- Hai-Bin Chen
- Ji-Cheng Li
-
Affiliations: Medical Research Center, Yue Bei People's Hospital, Shantou University Medical College, Wujiang, Shaoguan, Guangdong 512025, P.R. China, Department of Radiotherapy, Yue Bei People's Hospital, Shantou University Medical College, Wujiang, Shaoguan, Guangdong 512025, P.R. China, Institute of Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China, Department of Histology and Embryology, Shantou University Medical College, Shantou, Guangdong 515041, P.R. China - Published online on: February 15, 2021 https://doi.org/10.3892/ijo.2021.5188
- Article Number: 9
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wee JT, Ha TC, Loong SL and Qian CN: Is nasopharyngeal cancer really a 'Cantonese cancer'? Chin J Cancer. 29:517–526. 2010. View Article : Google Scholar : PubMed/NCBI | |
Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y and Ma J: Validation of the 8th edition of the uicc/ajcc staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw. 15:913–919. 2017. View Article : Google Scholar : PubMed/NCBI | |
Roy Chattopadhyay N, Das P, Chatterjee K and Choudhuri T: Higher incidence of nasopharyngeal carcinoma in some regions in the world confers for interplay between genetic factors and external stimuli. Drug Discov Ther. 11:170–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI | |
Janvilisri T: Omics-based identification of biomarkers for nasopharyngeal carcinoma. Dis Markers. 2015:7621282015. View Article : Google Scholar : PubMed/NCBI | |
Lee KT, Tan JK, Lam AK and Gan SY: MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol. 103:1–9. 2016. View Article : Google Scholar : PubMed/NCBI | |
Xiao L, Xiao T, Wang ZM, Cho WC and Xiao ZQ: Biomarker discovery of nasopharyngeal carcinoma by proteomics. Expert Rev Proteomics. 11:215–225. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, et al: Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 381:1124–1135. 2019. View Article : Google Scholar : PubMed/NCBI | |
Song C, Cheng P, Cheng J, Zhang Y, Sun M, Xie S and Zhang X: Differential diagnosis of nasopharyngeal carcinoma and nasopharyngeal lymphoma based on DCE-MRI and RESOLVE-DWI. Eur Radiol. 30:110–118. 2020. View Article : Google Scholar | |
Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al: NCCN guidelines insights: Head and neck cancers, version 1. 2018.J Natl Compr Canc Netw. 16:479–490. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun XS, Xiao BB, Lu ZJ, Liu SL, Chen QY, Yuan L, Tang LQ and Mai HQ: Stratification of candidates for induction chemotherapy in Stage III-IV nasopharyngeal carcinoma: A large cohort study based on a comprehensive prognostic model. Front Oncol. 28:2552020. View Article : Google Scholar | |
Wang YW, Ho SY, Lee SW, Chen CC, Litsu S, Huang WT, Yang CC, Lin CH, Chen HY and Lin LC: Induction chemotherapy improved long term outcomes in stage IV locoregional advanced nasopharyngeal carcinoma. Int J Med Sci. 17:568–576. 2020. View Article : Google Scholar : PubMed/NCBI | |
Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, et al: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer. 75:14–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
Jin BY, Zhang GY, Lin KR, Chen XP, Cui JH, Wang YJ and Luo W: Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT). PLoS One. 12:e01722642017. View Article : Google Scholar : PubMed/NCBI | |
Zhang G, Zhang K, Li C, Li Y, Li Z, Li N, Zhou Q and Shen L: Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy. Biosci Rep. May 14–2019.Epub ahead of print. View Article : Google Scholar | |
Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B, Shahi S, Rai R, Ali J and Jiang W: Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol. 15:662020. View Article : Google Scholar : PubMed/NCBI | |
Wang HY, Chang YL, To KF, Hwang JS, Mai HQ, Feng YF, Chang ET, Wang CP, Kam MK, Cheah SL, et al: A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer. 35:412016. View Article : Google Scholar : PubMed/NCBI | |
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized inter-group study 0099. J Clin Oncol. 16:1310–1317. 1998. View Article : Google Scholar : PubMed/NCBI | |
Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Liu TX, Siu L, Tan T, Chan LK, Ng WT, et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analysesof NPC-9901 and NPC-9902 trials. Eur J Cancer. 47:656–666. 2011. View Article : Google Scholar | |
Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF and Ma J: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 71:1356–1364. 2008. View Article : Google Scholar : PubMed/NCBI | |
Liang H, Xu Y, Chen M, Zhong W, Wang M and Zhao J: Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer. 11:1068–1075. 2020. View Article : Google Scholar : PubMed/NCBI | |
Jiang W, Liu N, Chen XZ, Sun Y, Li B, Ren XY, Qin WF, Jiang N, Xu YF, Li YQ, et al: Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma. Mol Cancer Ther. 14:2864–2873. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen ZT, Liang ZG and Zhu XD: A review: Proteomics in nasopharyngeal carcinoma. Int J Mol Sci. 16:15497–15530. 2015. View Article : Google Scholar : PubMed/NCBI | |
Del Giacco and Cattaneo C: Introduction to genomics. Methods Mol Biol. 823:79–88. 2012. View Article : Google Scholar | |
Berger MF and Mardis ER: The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 15:353–365. 2018. View Article : Google Scholar : PubMed/NCBI | |
Donnelly D III, Aung PP and Jour G: The '-OMICS' facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers. Semin Cancer Biol. 59:165–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
Tsang CM, Lui VW, Bruce JP, Pugh TJ and Lo KW: Translational genomics of nasopharyngeal cancer. Semin Cancer Biol. 61:84–100. 2020. View Article : Google Scholar | |
Yang H, Yu K, Zhang R, Li J, Wei X, Zhang Y, Zhang C, Xiao F, Zhao D, Lin X, et al: The HLA-DRB1 allele polymorphisms and nasopharyngeal carcinoma. Tumour Biol. 37:7119–7128. 2016. View Article : Google Scholar : PubMed/NCBI | |
Guo XG and Xia Y: The interleukin-18 promoter-607C>A polymorphism contributes to nasopharyngeal carcinoma risk: Evidence from a meta-analysis including 1,886 subjects. Asian Pac J Cancer Prev. 14:7577–7781. 2013. View Article : Google Scholar | |
Yi M, Cai J, Li J, Chen S, Zeng Z, Peng Q, Ban Y, Zhou Y, Li X, Xiong W, et al: Rediscovery of NF-κB signaling in nasopharyngeal carcinoma: How genetic defects of NF-κB pathway interplay with EBV in driving oncogenesis? J Cell Physiol. 233:5537–5549. 2018. View Article : Google Scholar | |
Tam V, Patel N, Turcotte M, Bosse Y, Paré G and Meyre D: Benefits and limitations of genome-wide association studies. Nat Rev Genet. 20:467–484. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhou P, Liu S, Ji NN, Zhang S, Wang P, Lin B, Yang P, Lin XT, Cai YZ, Wang ZM, et al: Association between variant alleles of major histocompatibility complex class II regulatory genes and nasopharyngeal carcinoma susceptibility. Eur J Cancer Prev. 29:531–537. 2020. View Article : Google Scholar : PubMed/NCBI | |
Niu Y, Zhou G, Wang Y, Qin J, Ping J, Zhang Q, Han BW, Liu YX, Yang C, Zhai Y, et al: Association of MCP-1 promoter polymorphism with susceptibility to nasopharyngeal carcinoma. J Cell Biochem. 120:6661–6670. 2019. View Article : Google Scholar | |
Ban EZ, Lye MS, Chong PP, Yap YY, Lim SY and Abdul Rahman H: Haplotype CGC from XPD, hOGG1 and ITGA2 polymorphisms increases the risk of nasopharyngeal carcinoma in Malaysia. PLoS One. 12:e01872002017. View Article : Google Scholar : PubMed/NCBI | |
Lourembam DS, Singh AR, Sharma TD, Singh TS, Singh TR and Singh LS: Evaluation of risk factors for nasopharyngeal carcinoma in a high-risk area of India, the Northeastern region. Asian Pac J Cancer Prev. 16:4927–4935. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zheng H, Dai W, Cheung AK, Ko JM, Kan R, Wong BW, Leong MM, Deng M, Kwok TC, Chan JY, et al: Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 113:11283–11288. 2016. View Article : Google Scholar | |
Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, et al: Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Commun. 8:141212017. View Article : Google Scholar | |
Tsao SW, Yip YL, Ysang CM, Pang PS, Lau VM, Zhang G and Lo KW: Etiology factors of nasopharyngeal carcinoma. Oral Oncol. 50:330–338. 2014. View Article : Google Scholar : PubMed/NCBI | |
Anderson EN Jr, Anderson ML and Ho HC: Environmental backgrounds of young Chinese nasopharyngeal carcinoma patients. IARC Sci Publ. 231–239. 1978.PubMed/NCBI | |
Tan C, Chen H, Wu T and Xia C: The prediction of nasopharyngeal carcinoma mortality based on soil element levels in China. Biol Trace Elem Res. 138:139–147. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yu G, Hsu WL, Coghill AE, Yu KJ, Wang CP, Lou PJ, Liu Z, Jones K, Vogt K, Wang M, et al: Whole-exome sequencing of nasopharyngeal carcinoma families reveals novel variants potentially involved in nasopharyngeal carcinoma. Sci Rep. 9:99162019. View Article : Google Scholar : PubMed/NCBI | |
Liu Z, Goldstein AM, Hsu WL, Yu KJ, Chien YC, Ko JY, Jian JJ, Tsou YA, Leu YS, Liao LJ, et al: Evaluation of rare and common variants from suspected familial or sporadic nasopharyngeal carcinoma (NPC) susceptibility genes in sporadic NPC. Cancer Epidemiol Biomarkers Prev. 28:1682–1686. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen EE and Onel K: Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 24:1222–1228. 2015. View Article : Google Scholar : PubMed/NCBI | |
Mokni-Baizing N, Gorgi Y, Elghourabi M, Makhlouf M, Boussen H, Gritli S, Elmay M, Gamoudi A and Elmay A: HLA-A*26-A*30 and HLA-DRB1*10 could be predictors of nasopharyngeal carcinoma risk in high-risk Tunisian families. J Oral Sci. 59:289–296. 2017. View Article : Google Scholar | |
Friborg J, Wohlfahrt J, Koch A, Storm H, Olsen OR and Melbye M: Cancer susceptibility in nasopharyngeal carcinoma families-a population-based cohort study. Cancer Res. 65:8567–8572. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kerns SL, West CM, Andreassen CN, Barnett GC, Bentzen SM, Burnet NG, Dekker A, De Ruysscher D, Dunning A, Parliament M, et al: Radiogenomics: The search for genetic predictors of radiotherapy response. Future Oncol. 10:2391–2406. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chen W and Hu GH: Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med. 12:23–32. 2015.PubMed/NCBI | |
Rattay T and Talbot CJ: Finding the genetic determinants of adverse reactions to radiotherapy. Clin Oncol (R Coll Radiol). 26:301–308. 2014. View Article : Google Scholar | |
Ma WL, Liu R, Huang LH, Zou C, Huang J, Wang J, Chen SJ, Meng XG, Yang JK, Li H, et al: Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma. Clin Exp Pharmacol Physiol. 44:539–548. 2017. View Article : Google Scholar : PubMed/NCBI | |
Le Z, Niu X, Chen Y, Ou X, Zhao G, Liu Q, Tu W, Hu C, Kong L and Liu Y: Predictive single nucleotide polymorphism markers for acute oral mucositis in patients with nasopharyngeal carcinoma treated with radiotherapy. Oncotarget. 8:63026–63037. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L, Chen S, Li J, Yuan H, Yang G, et al: Genetic polymorphisms of Wnt/β-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 7:82528–82537. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Guo C, Gong X, Ao F, Huang Y, Huang L, Tang Y, Jiang C, Xie X, Dong Q, et al: The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo) radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 8:78633–78641. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhai XM, Hu QC, Gu K, Wang JP, Zhang JN and Wu YW: Significance of XRCC1 Codon399 polymorphisms in Chinese patients with locally advanced nasopharyngeal carcinoma treated with radiation therapy. Asia Pac J Clin Oncol. 12:e125–e132. 2016. View Article : Google Scholar | |
Chen H, Wu M, Li G, Hua L, Chen S and Huang H: Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore). 96:e82022017. View Article : Google Scholar | |
Guo XB, Ma WL, Liu LJ, Huang YL, Wang J, Huang LH, Peng XD, Yin JY, Li JG, Chen SJ, et al: Effects of gene polymorphisms in the endoplasmic reticulum stress pathway on clinical outcomes of chemoradiotherapy in Chinese patients with nasopharyngeal carcinoma. Acta Pharmacol Sin. 38:571–580. 2017. View Article : Google Scholar : PubMed/NCBI | |
Tan J, Jiang L, Cheng X, Wang C, Chen J, Huang X, Xie P, Xia D, Wang R and Zhang Y: Association between VEGF-460T/C gene polymorphism and clinical outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Onco Targets Ther. 10:909–918. 2017. View Article : Google Scholar : PubMed/NCBI | |
Tsao SW, Tsang CM and Lo KW: Epstein-barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 372:201602702017. View Article : Google Scholar : PubMed/NCBI | |
Shen JJ, Niu WN, Zhou M, Zhou F, Zhang HY and Wang L: Association of Epstein Barr virus A73 gene polymorphism with nasopharyngeal carcinoma. Genet Test Mol Biomarkers. 19:187–190. 2015. View Article : Google Scholar | |
Wu S, Liu W, Li H, Zhao Z, Yang Y, Xiao H, Song Y and Luo B: Conservation and polymorphism of EBV RPMS1 gene in EBV-associated tumors and healthy individuals from endemic and non-endemic nasopharyngeal carcinoma areas in China. Virus Res. 250:75–80. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tay JK, Chan SH, Lim CM, Siow CH, Goh HL and Loh KS: The role of Epstein-Barr virus DNA load and serology as screening tools for nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 155:274–280. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chan KC, Woo JK, King A, Zee BC, Lam WK, Chan SL, Chu SW, Mak C, Tse IO, Leung SY, et al: Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 377:513–522. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lam WK, Chan KC and Lo YM: Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol. 247:641–649. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zeng Z, Fan S, Zhang X, Li S, Zhou M, Xiong W, Tan M, Zhang W and Li G: Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. Clin Transl Oncol. 18:206–211. 2016. View Article : Google Scholar | |
Arai A, Yamaguchi T, Komatsu H, Imadome K, Kurata M, Nagata K and Miura O: Infectious mononucleosis accompanied by clonal proliferation of EBV-infected cells and infection of CD8-positive cells. Int J Hematol. 99:671–675. 2014. View Article : Google Scholar : PubMed/NCBI | |
Banko AV, Lazarevic IB, Karalic DZ, Djukic VB, Cupic MD, Stevanovic G and Jovanovic TP: The sequence analysis of Epstein-Barr virus EBNA1 gene: Could viral screening markers for nasopharyngeal carcinoma be identified? Med Mircobiol Immunol. 208:81–88. 2019. View Article : Google Scholar | |
Banko AV, Lazarevic IB, Folic MM, Djukic VB, Cirkovic AM, Karalic DZ, Cupic MD and Jovanovic TP: Characterization of the variability of Epstein-Barr virus genes in nasopharyngeal biopsies: Potential predictors for carcinoma progression. PLoS One. 11:e01534982016. View Article : Google Scholar : PubMed/NCBI | |
Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, et al: Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer. 121:2720–2729. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chatsirisupachai K, Palmer D, Ferreira S and de Magalhães JP: A human tissue-specific transcriptomic analysis reveals a complex relationship between aging, cancer, and cellular senescence. Aging Cell. 18:e130412019. View Article : Google Scholar : PubMed/NCBI | |
Sager M, Yeat NC, Pajaro-Van der Stadt S, Lin C, Ren Q and Lin J: Transcriptomics in cancer diagnostics: Developments in technology, clinical research and commercialization. Expert Rev Mol Diagn. 15:1589–1603. 2015. View Article : Google Scholar : PubMed/NCBI | |
Moor AE and Itzkovitz S: Spatial transcriptomics: Paving the way for tissue-level systems biology. Curr Poin Biotechnol. 46:126–133. 2017. View Article : Google Scholar | |
Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang LJ, Chou YF, Chen PR, Su B, Hsu YC, Chang CH and Lee JW: Differential miRNA expression in repeated recurrence of nasopharyngeal carcinoma. Cancer Lett. 344:188–194. 2014. View Article : Google Scholar | |
Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen KH and Li Y: microRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep. 25:1353–1363. 2011.PubMed/NCBI | |
Lu T, Guo Q, Lin K, Chen H, Chen Y, Xu Y, Lin C, Su Y, Chen Y, Chen M, et al: Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma. Cancer Sci. 111:1711–1723. 2020. View Article : Google Scholar : PubMed/NCBI | |
Wu L, Wang J, Zhu D, Zhang S, Zhou X, Zhu W, Zhu J and He X: Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis. Cancer Biomark. 27:365–375. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hirai N, Wakisaka N, Knodo S, Aga M, Moriyama-Kita M, Ueno T, Nakanishi Y, Endo K, Sugimoto H, Murono S, et al: Potential interest in circulating miR-BART17-5p as a post-treatment biomarker for prediction of recurrence in Epstein-Barr virus-related nasopharyngeal carcinoma. PLoS One. 11:e01636092016. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Zou X, Wu L, Zhang S, Wang T, Liu P, Zhu W and Zhu J: Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection. Cancer Med. 9:1230–1241. 2020. View Article : Google Scholar | |
Yi SJ, Liu P, Chen BL, Ou-Yang L, Xiong WM and Su JP: Circulating miR-31-5p may be a potential diagnostic biomarker in nasopharyngeal carcinoma. Neoplasma. 66:825–829. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang H, Wei X, Wu B, Su J, Tan W and Yang K: Tumor-educated platelet miR-34c-3p and miR-18a-5p as potential liquid biopsy biomarkers for nasopharyngeal carcinoma diagnosis. Cancer Manag Res. 11:3351–3360. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wen W, Mai SJ, Lin HX, Zhang MY, Huang JL, Hua X, Lin C, Long ZQ, Lu ZJ, Sun XQ, et al: Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. J Transl Med. 17:1862019. View Article : Google Scholar : PubMed/NCBI | |
Wu L, Zheng K, Yan C, Pan X, Liu Y, Liu J, Wang F, Guo W, He X, Li J and Shen Y: Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. BMC Cancer. 19:8432019. View Article : Google Scholar : PubMed/NCBI | |
Wang M, Gu B, Chen X, Wang Y, Li P and Wang K: The function and therapeutic potential of Epstein-Barr virus-encoded MicroRNAs in cancer. Mol Ther Nucleic Acids. 17:657–668. 2019. View Article : Google Scholar : PubMed/NCBI | |
Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, Xiang B, Zhou M, Li X, Wu X, et al: The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma. J Cancer. 9:2852–2864. 2018. View Article : Google Scholar : PubMed/NCBI | |
Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, et al: RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 28:666–676. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li K, Zhu X, Li L, Ning R, Liang Z, Zeng F, Su F, Huang S, Yang X and Qu S: Identification of non-invasive biomarkers for predicting the radiosensitivity of nasopharyngeal carcinoma from serum microRNAs. Sci Rep. 10:51612020. View Article : Google Scholar : PubMed/NCBI | |
Wu J and Hann SS: Functions and roles of long-non-coding RNAs in human nasopharyngeal carcinoma. Cell Physiol Biochem. 45:1191–1204. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhao CX, Zhu W, Ba ZQ, Xu HJ, Liu WD, Zhu B, Wang L, Song YJ, Yuan S and Ren CP: The regulatory network of nasopharyngeal carcinoma metastasis with a focus on EBV, lncRNAs and miRNAs. Am J Cancer Res. 8:2185–2209. 2018.PubMed/NCBI | |
He B, Zeng J, Chao W, Chen X, Huang Y, Deng K, Huang Z, Li J, Dai M, Chen S, et al: Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget. 8:41166–41177. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan Z, Xiao N, Yao J and Li Z: Research progress on long non-coding RNA and radiotherapy. Med Sci Monit. 25:5757–5770. 2019. View Article : Google Scholar : PubMed/NCBI | |
Liu G, Zeng X, Wu B, Zhao J and Pan Y: RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with radiotherapy response of nasopharyngeal carcinoma and prognosis of head and neck cancer. Cancer Biol Ther. 21:139–146. 2020. View Article : Google Scholar : | |
Shuai M, Hong J, Huang D, Zhang X and Tian Y: Upregulation of circRNA_0000285 serves as a prognostic biomarker for nasopharyngeal carcinoma and is involved in radiosensitivity. Oncol Lett. 16:6495–6501. 2018.PubMed/NCBI | |
Gosho M, Nagashima K and Sato Y: Study designs and statistical analyses for biomarker research. Sensors (Basel). 12:8966–8986. 2012. View Article : Google Scholar | |
Cho WC: Mass spectrometry-based proteomics in cancer research. Expert Rev Proteomics. 14:725–727. 2017. View Article : Google Scholar : PubMed/NCBI | |
Tan HT, Lee YH and Chung MC: Cancer proteomics. Mass Spectrom Rev. 31:583–605. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Wu S, Stenoien DL and Paša-Tolić L: High-throughput proteomics. Annu Rev Anal Chem (Palo Alto Calif). 7:427–454. 2014. View Article : Google Scholar | |
Aslam B, Basit M, Nisar MA, Khurshid M and Rasool MH: Proteomics: Technologies and their applications. J Chromatogr Sci. 55:182–196. 2017. View Article : Google Scholar : PubMed/NCBI | |
EI-Sharkawy A, Al Zaidan L and Malki A: Epstein-Barr virus-associated malignancies: Roles of viral oncoproteins in carcinogenesis. Front Oncol. 8:2652018. View Article : Google Scholar | |
Zamanian Azodi M, Rezaei Tavirani M, Rezaei Tavirani M, Vafaee R and Rostami-Nejad M: Nasopharyngeal carcinoma protein interaction mapping analysis via proteomic approaches. Asian Pac J Cancer Prev. 19:845–851. 2018.PubMed/NCBI | |
Cao Y: EBV based cancer prevention and therapy in nasopharyngeal carcinoma. NPJ Precis Oncol. 1:102017. View Article : Google Scholar | |
Schmidlin T, Garrigues L, Lane CS, Mulder TC, van Doorn S, Post H, de Graaf EL, Lemeer S, Heck AJ and Altelaar AF: Assessment of SRM, MRM(3), and DIA for the targeted analysis of phosphorylation dynamics in non-small cell lung cancer. Proteomics. 16:2193–2205. 2016. View Article : Google Scholar : PubMed/NCBI | |
Luo Y, Mok TS, Lin X, Zhang W, Cui Y, Guo J, Chen X, Zhang T and Wang T: SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma. Sci Rep. 7:411912017. View Article : Google Scholar : PubMed/NCBI | |
Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ and Butler LM: Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants. Mol Cell Proteomics. 17:1470–1486. 2018. View Article : Google Scholar : PubMed/NCBI | |
Nakamura K, Hirayama-Kurogi M, Ito S, Kuno T, Yoneyama T, Obuchi W, Terasaki T and Ohtsuki S: Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM. Proteomics. 16:2106–2117. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sun X, Chen Y, Tan J and Qi X: Serum IRS-1 acts as a novel biomarker for diagnosis in patients with nasopharyngeal carcinoma. Int J Clin Exp Pathol. 11:3685–3690. 2018. | |
Coghill AE, Pfeiffer RM, Proietti C, Hus WL, Chien YC, Lekiffre L, Krause L, Teng A, Pablo J, Yu KJ, et al: Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan. Clin Cancer Res. 24:1305–1314. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lin LH, Xu YW, Huang LS, Hong CQ, Zhai TT, Liao LD, Lin WJ, Xu LY, Zhang K, Li EM and Peng YH: Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin Proteomics. 14:62017. View Article : Google Scholar : PubMed/NCBI | |
Gong D, Li Z, Ding R, Cheng M, Huang H, Liu A, Kang M, He H, Xu Y, Shao J, et al: Extensive serum biomarker analysis in patients with nasopharyngeal carcinoma. Cytokine. 118:107–114. 2019. View Article : Google Scholar | |
Meng H, Zhu X, Li L, Liang Z, Li X, Pan X, Zeng F and Qu S: Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry based comparative proteomic approach. Int J Mol Med. 40:1152–1164. 2017. View Article : Google Scholar : PubMed/NCBI | |
Manes NP and Nita-Lazar A: Application of targeted mass spectrometry in bottom-up proteomics for systems biology research. J Proteomics. 189:75–90. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun Y, Guo W, Bai Y, Ge M, Hu C, Wu S, Hao J, Gao M, Pan J, Dong P, et al: Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study. Oral Dis. 26:285–294. 2020. View Article : Google Scholar | |
Monti C, Zilocchi M, Colugnat I and Alberio T: Proteomics turns functional. J Proteomics. 198:36–44. 2019. View Article : Google Scholar | |
Xiao Z and Chen Z: Deciphering nasopharyngeal carcinoma pathogenesis via proteomics. Expert Rev Proteomics. 16:475–485. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang X: Cancer moonshot 2020: A new march of clinical and translational medicine. Clin Transl Med. 5:112016. View Article : Google Scholar : PubMed/NCBI | |
Fiore LD, Rodriguez H and Shriver CD: Collaboration to accelerate proteogenomics cancer care: The department of veterans affairs, department of defense, and the national cancer institute 's applied proteogenomics organizational learning and outcomes (APOLLO) network. Clin Pharmacol Ther. 101:619–621. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rinschen MM, Ivanisevic J, Giera M and Siuzdak G: Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 20:353–367. 2019. View Article : Google Scholar : PubMed/NCBI | |
Guijas C, Montenegro-Burke JR, Warth B, Spilker ME and Siuzdak G: Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol. 36:316–320. 2018. View Article : Google Scholar : PubMed/NCBI | |
Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD and McLean JA: Untargeted metabolomics strategies-challenges and emerging directions. J Am Soc Mass Spectrom. 27:1897–1905. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li X, Wenes M, Romero P, Huang SC, Fendt SM and Ho PC: Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 16:425–441. 2019. View Article : Google Scholar : PubMed/NCBI | |
Yang M, Soga T and Pollard PJ: Oncometabolites: Linking altered metabolism with cancer. J Clin Invest. 123:3652–3658. 2013. View Article : Google Scholar : PubMed/NCBI | |
Li S, Fu L, Tian T, Deng L, Li H, Xia W and Gong Q: Disrupting SOD1 activity inhibits cell growth and enhances lipid accumulation in nasopharyngeal carcinoma. Cell Commun Signal. 16:282018. View Article : Google Scholar : PubMed/NCBI | |
Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, Shi F, Li N, Li Y, Du Q, et al: Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics. 8:2329–2347. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tang F, Xie C, Huang D, Wu Y, Zeng M, Yi L, Wang L, Mei W, Cao Y and Sun L: Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy. Clin Biochem. 44:711–718. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yi L, Dong N, Shi S, Deng B, Yun Y, Yi Z and Zhang Y: Metabolomic identification of novel biomarkers of nasopharyngeal carcinoma. RSC Adv. 4:59094–59101. 2014. View Article : Google Scholar | |
Luo MS, Huang GJ and Liu HB: Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma: A meta-analysis. Medicine (Baltimore). 98:e159512019. View Article : Google Scholar | |
Carayol M, Leitzmann MF, Ferrari P, Zamora-Ros R, Achaintre D, Stepien M, Schmidt JA, Travis RC, Overvad K, Tjønneland A, et al: Blood metabolic signatures of body mass index: A targeted metabolomics study in the EPIC cohort. J Proteome Res. 16:3137–3146. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xu J, Li J, Zhang R, He J, Chen Y, Bi N, Song Y, Wang L, Zhan Q and Abliz Z: Development of a metabolic pathway-based pseudo-targeted metabolomics method using liquid chromatography coupled with mass spectrometry. Talanta. 192:160–168. 2019. View Article : Google Scholar | |
Allinson JL: Clinical biomarker validation. Bioanalysis. 10:957–968. 2018. View Article : Google Scholar : PubMed/NCBI | |
Rhomdhoni AC, Kurniawan P and Hidayati T: Correlation between superoxide dismutase serum level alteration with neck metastatic tumor post cisplatin-paclitaxel chemotherapy response in nasopharyngeal carcinoma patients. Indian J Otolaryngol Head Neck Surg. 71(Suppl 1): S643–S646. 2019. View Article : Google Scholar | |
Jelonek K, Krzywon A, Jablonska P, Slominska EM, Smolenski RT, Polanska J, Rutkowski T, Mrochem-Kwarciak J, Skladowki K and Widlak P: Systemic effects of radiotherapy and concurrent chemo-radiotherapy in head and neck cancer patients-comparison of serum metabolome profiles. Metabolites. 10:602020. View Article : Google Scholar | |
Geyer PE, Voytik E, Treit PV, Doll S, Kleinhempel A, Niu L, Müller JB, Buchholtz ML, Bader JM, Teupser D, et al: Plasma proteome profiling to detect and avoid sample-related biases in biomarker studies. EMBO Mol Med. 11:e104272019. View Article : Google Scholar : PubMed/NCBI | |
Dufourd T, Robil N, Mallet D, Carcenac C, Boulet S, Brishoual S, Rabois E, Houeto JL, de la Grange P and Carnicella S: Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers. Biol Methods Protoc. 4:bpz0062019. View Article : Google Scholar | |
Lippi G, Banfi G, Buttarello M, Ceriotti F, Daves M, Dolci A, Caputo M, Giavarina D, Montagnana M, Miconi V, et al: Recommendations for detection and management of unsuitable samples in clinical laboratories. Clin Chem Lab Med. 45:728–736. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lam WKJ, Jiang P, Chan KCA, Cheng SH, Zhang H, Peng W, Tse OYO, Tong YK, Gai W, Zee BCY, et al: Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 115:E5115–E5124. 2018. View Article : Google Scholar : PubMed/NCBI | |
Elliott P and Peakman TC; UK Biobank: The UK biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 37:234–244. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gautam A, Donohue D, Hoke A, Miller SA, Srinivasan S, Sowe B, Detwiler L, Lynch J, Levangie M, Hammamieh R and Jett M: Investigating gene expression profiles of whole blood and peripheral blood mononuclear cells using multiple collection and processing methods. PLoS One. 14:e02251372019. View Article : Google Scholar : PubMed/NCBI | |
Leidinger P, Backes C, Rheinheimer S, Keller A and Meese E: Towards clinical applications of blood-borne miRNA signatures: The influence of the anticoagulant EDTA on miRNA abundance. PLoS One. 10:e01433212015. View Article : Google Scholar : PubMed/NCBI | |
Mathé E, Hays JL, Stover DG and Chen JL: The omics revolution continues: The maturation of high-throughput biological data sources. Yearb Med Inform. 27:211–222. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hasin Y, Seldin M and Lusis A: Multi-omics Approaches to Disease. Genome Biol. 18:832017. View Article : Google Scholar : PubMed/NCBI | |
Chakraborty S, Hosen MI, Ahmed M and Shekhar HU: Onco-multi-OMICS approach: A new frontier in cancer research. Biomed Res Int. 2018:98362562018. View Article : Google Scholar : PubMed/NCBI | |
Nicora G, Vitali F, Dagliati A, Geifman N and Bellazzi R: Integrated multi-omics analyses in oncology: A review of machine learning methods and tools. Front Oncol. 10:10302020. View Article : Google Scholar : PubMed/NCBI | |
Olivier M, Asmis R, Hawkins GA, Howard TD and Cox LA: The need for multi-omics biomarker signatures in precision medicine. Int J Mol Sci. 20:47812019. View Article : Google Scholar : |